The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2-) breast cancer: When might multigene assays be of value?

被引：4

作者：

Aapro, Matti ^{[1
]}

De Laurentiis, Michelino ^{[2
]}

Rea, Dan ^{[3
]}

Bargallo Rocha, Juan Enrique ^{[4
]}

Elizalde, Roberto ^{[5
]}

Landherr, Laszlo ^{[6
]}

Linderholm, Barbro ^{[7
,8
,9
]}

Mamounas, Eleftherios ^{[10
]}

Markopoulos, Christos ^{[11
]}

Neven, Patrick ^{[12
]}

Petrovsky, Alexander ^{[13
]}

Rouzier, Roman ^{[14
]}

Smit, Vincent ^{[15
]}

Svedman, Christer ^{[16
]}

Schneider, Daniel ^{[17
]}

Thomssen, Christoph ^{[18
]}

Martin, Miguel ^{[19
]}

机构：

[1] Clin Genolier, Genolier Breast Ctr, Postale POB 100,Route Muids 3, CH-1272 Genolier, Switzerland

[2] G Pascale Fdn, Dept Senol, Natl Canc Inst, Via Mariano Semmola, I-80131 Naples, Italy

[3] Univ Birmingham, Sch Canc Sci, Vincent Dr, Birmingham B15 2TT, W Midlands, England

[4] Inst Nacl Cancerol, Dept Surg, Av San Fernando 22,Col Sect 16 Delegaci Tlalpan, Mexico City 14080, DF, Mexico

[5] Hosp Dr I Pirovano, Div Ginecol & Mastol, Av Monroe 3555, Buenos Aires 1428, DF, Argentina

[6] Uzsoki Teaching Hosp, Dept Oncoradiol, Uzsoki 29-41, Budapest 1145, Hungary

[7] Sahlgrens Acad, Dept Oncol, Dubbsgatan 15, S-41345 Gothenburg, Sweden

[8] Univ Hosp, Dubbsgatan 15, S-41345 Gothenburg, Sweden

[9] Karolinska Univ Hosp, Karolinska Inst, Dept Oncol Pathol, Z1 00, S-17176 Stockholm, Sweden

[10] Univ Florida, Hlth Canc Ctr Orlando Hlth, 1400 S Orange Ave, Orlando 32806, FL USA

[11] Athens Univ, Med Sch, Dept Surg, Iassiou St 8, Athens 11521, Greece

[12] UZ Leuven, Multidisciplinary Breast Ctr & Gynaecol Oncol, Herestraat 49, B-3000 Leuven, Belgium

[13] Russian Canc Res Ctr, Dept Radiosurg, 23 Kashirskoye Shosse, Moscow, Russia

[14] Univ Versailles St Quentin, Inst Curie, Dept Surg, 35 Rue Dailly, F-92220 Paris St Cloud, France

[15] Leiden Univ, Med Ctr, Dept Pathol, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands

[16] Genom Hlth, Med Affairs, Quai Sujet 10, Stockholm, Sweden

[17] Int Genom Hlth, Quai Sujet 10, Geneva, Switzerland

[18] Martin Luther Univ Halle Wittenberg, Dept Gynaecol, Ernst Grube Str. 40, D-06120 Halle, Saale, Germany

[19] Univ Complutense, Hosp Gregorio Maranon, Inst Invest Sanitaria, C Dr Esquerdo 46, Madrid 28007, Spain

来源：

BREAST | 2017年 / 33卷

关键词：

Hormone receptor-positive; HER2-negative early breast cancer; Adjuvant chemotherapy; Multigene assay; Treatment decision; INTERNATIONAL EXPERT CONSENSUS; AMERICAN SOCIETY; DISTANT RECURRENCE; ADJUVANT THERAPY; WOMEN; CHEMOTHERAPY; MARKERS; RISK; RECOMMENDATIONS; VALIDATION;

D O I：

10.1016/j.breast.2017.01.012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: A modest proportion of patients with early stage hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer benefit from adjuvant chemotherapy. Traditionally, treatment recommendations are based on clinical/pathologic criteria that are not predictive of chemotherapy benefit Multigene assays provide prognostic and predictive information that can help to make more informed treatment decisions. The MAGIC survey evaluated international differences in treatment recommendations, how traditional parameters are used for making treatment choices, and for which patients treating physicians feel most uncertain about their decisions. Methods: The MAGIC survey captured respondents' demographics, practice patterns, relevance of traditional parameters for treatment decisions, and use of or interest in using multigene assays. Using this information, a predictive model was created to simulate treatment recommendations for 672 patient profiles. Results: The survey was completed by 911 respondents (879 clinicians, 32 pathologists) from 52 countries. Chemo-endocrine therapy was recommended more often than endocrine therapy alone, but there was substantial heterogeneity in treatment recommendations in 52% of the patient profiles; approximately every fourth physician provided a different treatment recommendation. The majority of physicians indicated they wanted to use multigene assays clinically. Lack of reimbursement/availability were the main reasons for non-usage. Conclusions: The survey reveals substantial heterogeneity in treatment recommendations. Physicians have uncertainty in treatment recommendations in a high proportion of patients with intermediate risk features using traditional parameters. In HR+, HER2- patients with early disease the findings highlight the need for additional markers that are both prognostic and predictive of chemotherapy benefit that may support more-informed treatment decisions. (C) 2017 Published by Elsevier Ltd.

引用

页码：191 / 199

页数：9

共 32 条

[1]

Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0

[2]

Abu-Khalf M, 2013, BREAST, V22, pS83, DOI [10.1016/j.breast2013.07.015, 10.1016/j.breast.2013.07.015]

[3] Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials [J].

Albain, K. ;

Anderson, S. ;

Arriagada, R. ;

Barlow, W. ;

Bergh, J. ;

Bliss, J. ;

Buyse, M. ;

Cameron, D. ;

Carrasco, E. ;

Clarke, M. ;

Correa, C. ;

Coates, A. ;

Collins, R. ;

Costantino, J. ;

Cutter, D. ;

Cuzick, J. ;

Darby, S. ;

Davidson, N. ;

Davies, C. ;

Davies, K. ;

Delmestri, A. ;

Di Leo, A. ;

Dowsett, M. ;

Elphinstone, P. ;

Evans, V. ;

Ewertz, M. ;

Gelber, R. ;

Gettins, L. ;

Geyer, C. ;

Goldhirsch, A. ;

Godwin, J. ;

Gray, R. ;

Gregory, C. ;

Hayes, D. ;

Hill, C. ;

Ingle, J. ;

Jakesz, R. ;

James, S. ;

Kaufmann, M. ;

Kerr, A. ;

MacKinnon, E. ;

McGale, P. ;

McHugh, T. ;

Norton, L. ;

Ohashi, Y. ;

Paik, S. ;

Pan, H. C. ;

Perez, E. ;

Peto, R. ;

Piccart, M. .

LANCET, 2012, 379 (9814) :432-444

[4] Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial [J].

Albain, Kathy S. ;

Barlow, William E. ;

Shak, Steven ;

Hortobagyi, Gabriel N. ;

Livingston, Robert B. ;

Yeh, I-Tien ;

Ravdin, Peter ;

Bugarini, Roberto ;

Boehner, Frederick L. ;

Davidson, Nancy E. ;

Sledge, George W. ;

Winer, Eric P. ;

Hudis, Clifford ;

Ingle, James N. ;

Perez, Edith A. ;

Pritchard, Kathleen I. ;

Shepherd, Lois ;

Gralow, Julie R. ;

Yoshizawa, Carl ;

Allred, D. Craig ;

Osborne, C. Kent ;

Hayes, Daniel F. .

LANCET ONCOLOGY, 2010, 11 (01) :55-65

[5]

American Society of Clinical Oncology, ASCO BREAST CANC GUI

[6] Effect of Three Decades of Screening Mammography on Breast-Cancer Incidence [J].

Bleyer, Archie ;

Welch, H. Gilbert .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (21) :1998-2005

[7] 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer [J].

Cardoso, F. ;

van't Veer, L. J. ;

Bogaerts, J. ;

Slaets, L. ;

Viale, G. ;

Delaloge, S. ;

Pierga, J. -Y. ;

Brain, E. ;

Causeret, S. ;

DeLorenzi, M. ;

Glas, A. M. ;

Golfinopoulos, V. ;

Goulioti, T. ;

Knox, S. ;

Matos, E. ;

Meulemans, B. ;

Neijenhuis, P. A. ;

Nitz, U. ;

Passalacqua, R. ;

Ravdin, P. ;

Rubio, I. T. ;

Saghatchian, M. ;

Smilde, T. J. ;

Sotiriou, C. ;

Stork, L. ;

Straehle, C. ;

Thomas, G. ;

Thompson, A. M. ;

van der Hoeven, J. M. ;

Vuylsteke, P. ;

Bernards, R. ;

Tryfonidis, K. ;

Rutgers, E. ;

Piccart, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (08) :717-729

[8] Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 [J].

Coates, A. S. ;

Winer, E. P. ;

Goldhirsch, A. ;

Gelber, R. D. ;

Gnant, M. ;

Piccart-Gebhart, M. ;

Thuerlimann, B. ;

Senn, H. -J. .

ANNALS OF ONCOLOGY, 2015, 26 (08) :1533-1546

[9] Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy [J].

Dowsett, Mitch ;

Sestak, Ivana ;

Lopez-Knowles, Elena ;

Sidhu, Kalvinder ;

Dunbier, Anita K. ;

Cowens, J. Wayne ;

Ferree, Sean ;

Storhoff, James ;

Schaper, Carl ;

Cuzick, Jack .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (22) :2783-+

[10] The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use [J].

Eiermann, W. ;

Rezai, M. ;

Kuemmel, S. ;

Kuehn, T. ;

Warm, M. ;

Friedrichs, K. ;

Schneeweiss, A. ;

Markmann, S. ;

Eggemann, H. ;

Hilfrich, J. ;

Jackisch, C. ;

Witzel, I. ;

Eidtmann, H. ;

Bachinger, A. ;

Hell, S. ;

Blohmer, J. .

ANNALS OF ONCOLOGY, 2013, 24 (03) :618-624

← 1 2 3 4 →